Goldman Sachs analyst Corinne Johnson resumed coverage of Rhythm Pharmaceuticals (RYTM) with a Buy rating and $97 price target The firm is positive on the size of the hypothalamic obesity market and estimate a peak sales opportunity for Rhythm at $1.9B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals Reports Positive Phase 2 Trial Results
- Rhythm Pharmaceuticals price target raised to $102 from $88 at Leerink
- Rhythm Pharmaceuticals announces $150M common stock offering
- Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham
- Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA